Who owns SCMP - SUCAMPO PHARMACEUTICALS INC - CL A based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

SUCAMPO PHARMACEUTICALS INC - CL A (SCMP) Institutional Ownership

Q: What is CUSIP 864909106?

CUSIP 864909106 is the security identifier used in SEC filing datasets for SCMP - SUCAMPO PHARMACEUTICALS INC - CL A.

CUSIP: 864909106

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2018

Type / Class: Equity / CL A
Symbol: SCMP

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 864909106?
CUSIP 864909106 identifies SCMP - SUCAMPO PHARMACEUTICALS INC - CL A in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 864909106:

Q2 2018 (0 holders) Q1 2018 (3 holders) Q4 2017 (181 holders) Q3 2017 (175 holders) Q2 2017 (164 holders) Q1 2017 (165 holders) Q4 2016 (164 holders) Q3 2016 (119 holders) Q2 2016 (133 holders) Q1 2016 (128 holders)

Institutional Holders of SUCAMPO PHARMACEUTICALS INC - CL A (SCMP) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2018 Q2	0	$0	-$21,000				0
2018 Q1	1,156	$21,000	-$643,738,188	$0	$0	$18.23	3
2017 Q4	35,979,804	$645,840,173	+$127,689,743	$7,084,000	$7,057,000	$17.95	181
2017 Q3	30,525,524	$360,078,077	+$55,983,004	$301,000	$1,164,000	$11.80	175
2017 Q2	25,796,915	$270,916,337	-$4,424,401	$683,000	$1,227,000	$10.50	164
2017 Q1	26,110,803	$287,159,626	+$35,558,865	$915,000	$1,155,000	$11.00	165
2016 Q4	25,071,854	$339,695,426	+$84,540,901	$1,607,000	$996,000	$13.55	164
2016 Q3	18,833,299	$231,832,072	+$4,798,690	$414,000	$571,100	$12.31	119
2016 Q2	18,628,250	$204,340,372	-$18,153,040	$450,000	$391,000	$10.97	133
2016 Q1	20,377,935	$222,674,197	-$27,845,160	$434,000	$203,000	$10.93	128
2015 Q4	22,128,299	$382,909,130	-$34,407,920	$597,000	$806,000	$17.29	145
2015 Q3	23,555,312	$468,161,374	+$62,534,690	$1,860,000	$991,000	$19.87	151
2015 Q2	20,767,624	$341,241,430	+$46,608,586	$688,000	$601,000	$16.43	130
2015 Q1	18,059,719	$281,029,737	+$80,464,657	$761,000	$344,000	$15.56	122
2014 Q4	12,717,537	$181,788,222	+$27,118,992	$250,000	$740,000	$14.28	90
2014 Q3	9,994,914	$64,962,279	-$2,259,298	$0		$6.50	67
2014 Q2	10,330,560	$71,260,571	-$5,268,906	$262,000		$6.90	71
2014 Q1	11,070,993	$79,149,672	+$9,135,075	$1,054,000		$7.15	80